{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:50:50Z","timestamp":1787313050479,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI18\/01751"],"award-info":[{"award-number":["PI18\/01751"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>The aim of this study was to identify factors associated with non-adherence to tuberculosis (TB) preventive treatment among contacts with latent TB infection for new cases of pulmonary TB cases reported in Catalonia in 2019\u20132021. All contacts aged 18 years or older with a latent TB infection who received a TB preventive treatment were included in the study. The Chi square test and the odds ratios (OR) were used to assess the association between non-adherence to TB preventive treatment and the study variables; a p &lt; 0.05 was considered statistically significant. Multiple logistic regression analysis was used to detect the independent factors associated with TB preventive treatment non-adherence; a p &lt; 0.05 was considered statistically significant. The percentage of non-adherence to TB preventive treatment found in this study was 23.7%. A multivariable logistic regression analysis determined that the following factors were significantly associated with TB preventive treatment non-adherence among adult contacts: \u201cexposure at school or workplace\u201d (aOR = 3.34), \u201cexposure to an index case without laboratory confirmation of TB\u201d (aOR = 2.07), \u201cimmigrant contact\u201d (aOR = 1.81), \u201cmale gender\u201d (aOR = 1.75) and \u201cexposure duration &lt; 6 h per week or sporadic\u201d (aOR = 1.60. By contrast, the factor \u201cshort-term TB preventive treatment regimen\u201d (aOR = 0.38) was significantly associated with a lower treatment non-adherence. Adherence to TB preventive treatment should be improved among adult contacts of TB pulmonary cases with latent TB infection by recommending short-term treatment regimens and by developing health education activities, with a greater focus on contacts with factors associated with treatment non-adherence.<\/jats:p>","DOI":"10.3390\/tropicalmed9030054","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:52:55Z","timestamp":1709034775000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factors Associated with Non-Adherence to Tuberculosis Preventive Treatment among Adult Contacts of Pulmonary Tuberculosis Cases with Latent Tuberculosis Infection in Catalonia, Spain, in 2019\u22122021"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-2971","authenticated-orcid":false,"given":"Pedro","family":"Plans-Rubi\u00f3","sequence":"first","affiliation":[{"name":"Public Health Agency of Catalonia, 00805 Barcelona, Spain"},{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Godoy","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 de la Salut (ICS), 08007 Lleida, Spain"},{"name":"Institut de Recerca Biom\u00e8dica (IRB Lleida), University of Lleida, 25006 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-9238","authenticated-orcid":false,"given":"Diana","family":"Toledo","sequence":"additional","affiliation":[{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Medicine, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Medicine, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-111X","authenticated-orcid":false,"given":"Joan","family":"Cayl\u00e0","sequence":"additional","affiliation":[{"name":"Barcelona Tuberculosis Research Unit Foundation, 08008 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-0236","authenticated-orcid":false,"given":"Ignasi","family":"Parron","sequence":"additional","affiliation":[{"name":"Public Health Agency of Catalonia, 00805 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-2459","authenticated-orcid":false,"given":"Joan Pau","family":"Millet","sequence":"additional","affiliation":[{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Epidemiology Service, Public Health Agency of Barcelona, 08023 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-7286","authenticated-orcid":false,"given":"Pere","family":"Godoy","sequence":"additional","affiliation":[{"name":"CIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Institut Catal\u00e0 de la Salut (ICS), 08007 Lleida, Spain"},{"name":"Institut de Recerca Biom\u00e8dica (IRB Lleida), University of Lleida, 25006 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent Tuberculosis Infection","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"World Health Organization (WHO) (2023). Global Tuberculosis Report 2023, World Health Organization. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/373828\/9789240083851-eng.pdf?sequence=1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","article-title":"Progression from latent infection to active disease in dynamic tuberculosis transmission models: A systematic review of the validity of modelling assumptions","volume":"18","author":"Menzies","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","unstructured":"World Health Organization (WHO) (2015). The End TB Strategy, World Health Organization. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/331326\/WHO-HTM-TB-2015.19-eng.pdf?sequence=1."},{"key":"ref_5","unstructured":"United Nations (UN) (2024, January 12). Resolution Adopted by the General Assembly on 5 October 2023. Political Declaration of the High-Level Meeting on the Fight against Tuberculosis. Advancing Science, Finance and Innovation, and Their Benefits, to Urgently End the Global Tuberculosis Epidemic, in Particular by Ensuring Equitable Access to Prevention, Testing, Treatment and Care. Available online: https:\/\/www.who.int\/activities\/preparing-for-the-un-high-level-meeting-on-the-fight-against-tuberculosis--2023."},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2018). Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management, WHO. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/260233\/9789241550239-eng.pdf?sequence=1."},{"key":"ref_7","unstructured":"World Health Organization (WHO) (2020). Consolidated Guidelines on Tuberculosis. Module 1: Prevention\u2014Tuberculosis Preventive Treatment, World Health Organization. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/331170\/9789240001503-eng.pdf?sequence=1."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: A network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Martin-Sanchez, M., Brugueras, S., de Andr\u00e9s, A., Simon, P., Gorrindo, P., Ros, M., Masdeu, E., Millet, J.-P., Cayla, J.A., and Orcau, A. (2019). Tuberculosis incidence among infected contacts detected through contact tracing of smear-positive patients. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215322"},{"key":"ref_11","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2018). Programmatic Management of Latent Tuberculosis Infection in the European Union, ECDC. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/October-2018-Programmatic-management-LTBI-EU.pdf."},{"key":"ref_12","unstructured":"Departament de Salut (2023). Mem\u00f2ria de la Secretaria de Salut P\u00fablica, Departament de Salut. Available online: https:\/\/salutpublica.gencat.cat\/web\/.content\/minisite\/aspcat\/publicacio_formacio_recerca\/publicacions\/corporatives\/memoria-sp-2021.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e015108","DOI":"10.1136\/bmjopen-2016-015108","article-title":"Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: A simulation study","volume":"7","author":"Patel","year":"2017","journal-title":"BMJ Open"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Stuurman, A.L., Vonk Noordegraaf-Schouten, M., van Kessel, F., Oordt-Speets, A.M., Sandgren, A., and van der Werf, M.J. (2016). Interventions for improving adherence to treatment for latent tuberculosis infection: A systematic review. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1549-4"},{"key":"ref_15","first-page":"165","article-title":"Cumplimiento y efectividad del tratamiento de la infecci\u00f3n tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes","volume":"103","author":"Arias","year":"2018","journal-title":"Med. Clin."},{"key":"ref_16","first-page":"e1","article-title":"Cumplimiento del tratamiento de la infecci\u00f3n tuberculosa latente en una cohorte de contactos de enfermos de tuberculosis","volume":"92","author":"Godoy","year":"2018","journal-title":"Rev. Esp. Salud P\u00fablica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.aprim.2013.05.009","article-title":"Factores asociados a la adherencia en el tratamiento de la infecci\u00f3n tuberculosa","volume":"46","author":"Gallardo","year":"2014","journal-title":"Aten. Primaria"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Puyana Ortiz, J.D., Garc\u00e9s Rodr\u00edguez, A.C., Aznar, M.L., Espinosa Pereiro, J., S\u00e1nchez-Montalv\u00e1, A., Mart\u00ednez-Campreci\u00f3s, J., Saborit, N., Rodrigo-Pend\u00e1s, J.\u00c1., Garc\u00eda Salgado, G., and Broto Cortes, C. (2023). Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain. Trop. Med. Infect. Dis., 8.","DOI":"10.3390\/tropicalmed8070373"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1002\/hpm.2495","article-title":"Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature","volume":"33","author":"Liu","year":"2018","journal-title":"Int. J. Health Plan. Manag."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Schein, Y.L., Madebo, T., Andersen, H.E., Arnesen, T.M., Dyrhol-Riise, A.M., Tveiten, H., White, R.A., and Winje, B.A. (2018). Treatment completion for latent tuberculosis infection in Norway: A prospective cohort study. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3468-z"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5588\/ijtld.12.0692","article-title":"Completing treatment for latent tuberculosis: Patient background matters","volume":"17","author":"Kan","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_22","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: Systematic review of studies in the US and Canada","volume":"12","author":"Daftary","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S1473-3099(21)00052-9","article-title":"Initiation and completion of treatment for latent tuberculosis infection in migrants globally: A systematic review and meta-analysis","volume":"21","author":"Rustage","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: Results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: Opportunities and challenges","volume":"23","author":"Chee","year":"2018","journal-title":"Respirology"},{"key":"ref_27","first-page":"e38182","article-title":"Efficacy and Safety of Different Drug Regimens for Tuberculosis Preventive Treatment: A Systematic Review and Meta-Analysis","volume":"15","author":"Shah","year":"2023","journal-title":"Cureus"},{"key":"ref_28","unstructured":"World Health Organization (WHO) (2022). Implementing the End TB Strategy: Essentials, WHO. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240065093."},{"key":"ref_29","unstructured":"World Health Organization (WHO) (2015). Framework for Tuberculosis Elimination in Low-Incidence Countries, World Health Organization. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/132231\/9789241507707_eng.pdf?sequence=1."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"180035","DOI":"10.1183\/16000617.0035-2018","article-title":"Tuberculosis elimination: Where are we now?","volume":"27","author":"Matteelli","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Rosales-Klintz, S., Bruchfeld, J., Haas, W., Heldal, E., Houben, R.M.G.J., van Kessel, F., Mandelbaum, M., Matteelli., A., Migliori., G.B., and Oordt-Speets, A. (2019). Guidance for programmatic management of latent tuberculosis infection in the European Union\/European Economic Area. Eur. Respir. J., 53.","DOI":"10.1183\/13993003.02077-2018"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.acc.2023.03.003","article-title":"Advances in TB testing","volume":"115","author":"Pagaduan","year":"2023","journal-title":"Adv. Clin. Chem."},{"key":"ref_33","unstructured":"WHO (2024, January 20). Global TB Report 2023, Diagnostic Testing. Available online: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\/tb-diagnosis---treatment\/2.2-diagnostic-testing-for-tb."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"00315-2020","DOI":"10.1183\/23120541.00315-2020","article-title":"All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era","volume":"6","author":"Stagg","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/9\/3\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:05:42Z","timestamp":1760105142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/9\/3\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["tropicalmed9030054"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed9030054","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}